1-3 of 3
Axel Matzdorff, MD
Close
Sort by
Journal Articles

Variable Support Towards ASCO Recommendations for Venous Thromboembolism (VTE) Prophylaxis and Treatment in Patients with Cancer

Axel Matzdorff, MD PhD, Uwe Schwindel, MD, Michael Mueller, Hans Joachim Hutt, MD
Journal: Blood
Blood (2015) 126 (23): 5564.
https://doi.org/10.1182/blood.V126.23.5564.5564
Published: 2015
Journal Articles

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.

Richard F. Schlenk, MD, Konstanze Dohner, MD, Martina Kerz, Francisco del Valle, MD, Björn Heydrich, MD, Ingo Schmidt-Wolf, MD, Hans Pralle, MD, Katharina Götze, MD, Elisabeth Koller, MD, David Nachbaur, MD, Hans G. Mergenthaler, MD, Walter Fiedler, MD, Detlef Haase, MD, Stephan Kremers, MD, Matthias Theobald, MD, Axel Matzdorff, MD, Arnold Ganser, MD, Hartmut Dohner, MD
Journal: Blood
Blood (2006) 108 (11): 1949.
https://doi.org/10.1182/blood.V108.11.1949.1949
Published: 2006
Journal Articles

Treatment with Pegylated Interferon α (PegIntron) for High-Risk Essential Thrombocythemia: Results of a Phase II Study.

Christian Langer, MD, Eva Lengfelder, MD, Jurgen Thiele, MD, Hans M. Kvasnika, MD, Heike Pahl, PhD, Axel Matzdorff, MD, Barbara Stade, Stefanie Schauer, Heinz Gisslinger, MD, Hartmut Dohner, MD, Martin Griesshammer, MD
Journal: Blood
Blood (2004) 104 (11): 1522.
https://doi.org/10.1182/blood.V104.11.1522.1522
Published: 2004